Benitec Biopharma is a clinical-stage biotechnology company focused on developing gene therapies for rare genetic conditions. The company's sole clinical candidate is BB-301, an adeno-associated virus-based gene therapy for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a rare, inherited muscle disorder causing dysphagia and muscle weakness. BB-301 relies on Benitec's proprietary DNA-directed RNA interference (ddRNAi) platform, which applies a "silence and replace" mechanism to simultaneously silence the mutant PABPN1 gene and express a functional replacement protein after a single injection into pharyngeal muscle. Benitec is currently evaluating BB-301 in a Phase 1b/2a trial and holds Fast Track and Orphan Drug designations in the U.S. and Orphan Drug designation in the EU. Benitec has no approved products, generates no commercial revenue, and outsources all manufacturing to contract manufacturing organizations. The company's strategy involves advancing BB-301 to regulatory approval and monetizing the asset through out-licensing and co-development partnerships with larger pharmaceutical firms or via direct commercialization in select markets.